{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:04:45Z","timestamp":1791813885698,"version":"4.3.4"},"reference-count":84,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite advances in immunotherapies. Novel bispecific antibodies (BsAbs), including talquetamab, have shown promising efficacy in heavily pretreated patients, even those with triple\u2010 and penta\u2010refractory disease. Talquetamab, recently approved by the FDA and EMA, is indicated for patients who have progressed after at least three or four prior lines of therapy (LOTs). Administered following a step\u2010up dosing phase to manage cytokine release syndrome (CRS), talquetamab demonstrated a high overall response rate (ORR) of approximately 70%, including in patients previously treated with T\u2010cell redirecting therapies. Its safety profile is consistent with other BsAbs, with hematologic adverse events such as anemia and neutropenia commonly reported, alongside unique on\u2010target off\u2010tumor toxicities like dysgeusia and skin\u2010related events. Infections were less frequent compared to other BsAbs. The optimal sequencing of talquetamab and other therapies, including CAR\u2010T cell treatments, remains an area of active research, as resistance to anti\u2010BCMA therapies presents ongoing clinical challenges. Current trials are exploring the use of talquetamab in combination therapies, as well as therapeutic strategies post\u2010treating progression. The real\u2010world data further support talquetamab's efficacy, making it a valuable addition to the RRMM treatment landscape.<\/jats:p>","DOI":"10.1111\/ejh.14353","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T02:39:33Z","timestamp":1732761573000},"page":"386-399","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions"],"prefix":"10.1111","volume":"114","author":[{"given":"Caterina","family":"Labanca","sequence":"first","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Antonia","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-2404","authenticated-orcid":false,"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Lucia","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Olivito","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Puccio","sequence":"additional","affiliation":[{"name":"Laboratorio di Ricerca Traslazionale Azienda USL\u2010IRCSS Reggio Emilia  Emilia\u2010Romagna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"Scientific Directorate IRCCS of Reggio Emilia  Reggio Emilia Emilia\u2010Romagna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-7073","authenticated-orcid":false,"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"Gruppo Amici Dell'Ematologia Foundation\u2010GrADE  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-0726","authenticated-orcid":false,"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Ospedaliera Annunziata  Cosenza Italy"},{"name":"Department of Pharmacy, Health and Nutritional Science University of Calabria  Rende Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"issue":"1","key":"e_1_2_11_3_1","first-page":"13","article-title":"CD38 Antibodies in Multiple Myeloma: Back to the Future","volume":"131","author":"Van de Donk N. W.","year":"2018","journal-title":"Blood, the Journal of the American Society of Hematology"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25117"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01546-0"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205154"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2333376"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124298"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2299"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122895"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121731"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138831"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14121"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843612.41180.42"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000829612.28397.ba"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.001"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000983"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(01)00197-X"},{"key":"e_1_2_11_34_1","unstructured":"\u201cGPRC5D G Protein\u2010Coupled Receptor Class C g. up 5 Member D [Homo sapiens(Human)] \u201dGene ID: 55507 accessed Aug 2 2024."},{"key":"e_1_2_11_35_1","unstructured":"U.S. Food and Drug Administration \u201cTalveytm (Talquetamab\u2010Tgvs) Prescribing Information \u201d2023 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf."},{"key":"e_1_2_11_36_1","unstructured":"European Medicines Agency \u201cSummary of Opinion on Talvey (Talquetamab) \u201d2023 https:\/\/www.ema.europa.eu\/en\/documents\/smop\u2010initial\/chmp\u2010summary\u2010positive\u2010opinion\u2010talvey_en.pdf."},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02229-1"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202X.2004.12628.x"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1216"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2012.02679.x"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00625-9"},{"issue":"15","key":"e_1_2_11_43_1","first-page":"1232","article-title":"A T\u2010Cell\u2013Redirecting Bispecific G\u2010Protein\u2013Coupled Receptor Class 5 Member D x CD3 Antibody to Treat Multiple Myeloma","volume":"135","author":"Pillarisetti K.","year":"2020","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"16","key":"e_1_2_11_44_1","article-title":"Pivotal Phase 2 MonumenTAL\u20101 Results of Talquetamab (Tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"41","author":"Schinke C. D.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187242"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.07.031"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.003"},{"key":"e_1_2_11_49_1","unstructured":"Mayo Clinic \u201cMayo Stratification for Myeloma and Risk\u2010Adapted Therapy. Management of Teclistamab Cytokine Release Syndrome (CRS) and Immune Cell Associated Neurotoxicity Syndrome (ICANS) \u201d2024."},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00283-0"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8020"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181228"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8041"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/jtxs.12575"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.5005\/jcdp-9-3-72"},{"issue":"12","key":"e_1_2_11_56_1","first-page":"3639","article-title":"Evaluating dysphagia","volume":"61","author":"Spieker M. R.","year":"2000","journal-title":"American Family Physician"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.18900.1"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157988"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004588"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.7170"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.11.013"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1159\/000538047"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283931"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.478"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00885"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0020"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126145"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.10.006"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8032"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8003"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843624.82943.92"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000829564.55849.0d"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8002"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123713"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02797-x"},{"issue":"1","key":"e_1_2_11_78_1","first-page":"25","article-title":"Multiple Myeloma: Signaling Pathways and Targeted Therapy","volume":"5","author":"Lu Q.","year":"2024","journal-title":"Molecular Biology"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040988"},{"issue":"3","key":"e_1_2_11_80_1","first-page":"554","article-title":"B\u2010Cell Maturation Antigen\u2010Based Therapies Post\u2010Talquetamab in Relapsed or Refractory Multiple Myeloma","volume":"5","author":"Shrestha A.","year":"2024","journal-title":"British Journal of Haematology"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157485"},{"key":"e_1_2_11_82_1","article-title":"Forimtamig, a Novel GPRC5D Targeting T Cell Bispecific Antibody With 2\u2009+\u20091 Format for the Treatment of Multiple Myeloma","author":"Eckmann J.","year":"2024","journal-title":"Blood"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147983"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0004-z"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159353"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T22:00:56Z","timestamp":1739224856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/ejh.14353"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14353","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"2024-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}